Research To Practice | Oncology Videos

Featuring perspectives from Dr Matthew D Galsky, Prof Andrea Necchi and Dr Scott T Tagawa, including the following topics: Current and Future Management of Nonmetastatic Urothelial Bladder Cancer (UBC) Introduction (0:00) Management of non-muscle-invasive bladder cancer (5:30) Neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer (18:39) Management of nonmetastatic UBC in patients who are not candidates for cystectomy (27:55) Recent Advances in the Treatment of Metastatic UBC (mUBC) Selection and sequencing of therapy for platinum-eligible patients with FGFR wild-type mUBC (31:03) Selection and sequencing of therapy for platinum-ineligible patients with FGFR wild-type mUBC (41:26) Selection and sequencing of therapy for patients with FGFR-altered mUBC (45:07) Novel agents and strategies under investigation in UBC (53:53) CME information and select publications

Featuring perspectives from Dr Anthony El-Khoueiry, Dr Robin K (Katie) Kelley and Prof Arndt Vogel, includingthe following topics: Hepatocellular Carcinoma (HCC) Introduction (0:00) Adjuvant therapy for HCC (1:47) First-line systemic therapy for advanced/metastatic HCC (10:36) Management of HCC in the second-line setting and beyond (18:27) Biliary Tract Cancers (BTCs) First-line systemic therapy for metastatic BTCs (26:41) Management of metastatic cholangiocarcinoma with FGFR fusions/rearrangements (35:16) Management of metastatic cholangiocarcinoma with IDH1 mutations (43:54) Management of metastatic HER2-positive BTC (48:47) CME information and select publications

Featuring perspectives from Dr Philipp Harter, Dr David M O'Malley and Dr Shannon N Westin, including the following topics: Up-Front Treatment for Advanced Ovarian Cancer (OC) Introduction (0:00) Front-line maintenance therapy for patients with advanced OC (3:11) Adverse events associated with PARP inhibitors and implications for therapeutic selection (14:17) Other considerations for patients with advanced ovarian cancer and germline BRCA mutations: Management of the breast, role of genetic counseling, et cetera (31:03) The Evolving Management Paradigm for Relapsed/Refractory OC PARP inhibitors as later-line therapy for advanced OC (35:20) Use of mirvetuximab soravtansine in advanced OC (44:04) Novel Agents and Strategies Under Investigation for Advanced OC Upifitamab rilsodotin in advanced OC (50:10) Tumor treating fields in advanced OC (56:03) CME information and select publications

Featuring perspectives from Dr Komal Jhaveri, Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O'Shaughnessy, Dr Hope S Rugo and Prof Peter Schmid, including the following topics: Long-Term Management of HER2-Positive Breast Cancer Introduction (0:00) Management of CNS-only disease progression in patients with HER2-positive metastatic breast cancer (2:27) Synergy between tucatinib and HER2-targeted antibody-drug conjugates (5:24) Management of trastuzumab deruxtecan–related adverse events (7:41) Patient selection for and practical implementation of postadjuvant neratinib (13:23) Faculty presentation: Dr Krop (16:26) Optimizing the Management of ER-Positive Localized Breast Cancer Ovarian function suppression to preserve fertility and prevent premature ovarian insufficiency; interrupting adjuvant hormonal therapy to attempt pregnancy (24:56) Selection of patients for adjuvant tamoxifen monotherapy (29:05) Utility of genomic assays in the neoadjuvant setting; management of node-positive disease in postmenopausal patients with low-risk Recurrence Scores® (33:35) Selection between abemaciclib and ribociclib in the adjuvant setting (36:45) Potential utility of circulating tumor DNA assessment in breast cancer (41:58) Faculty presentation: Dr Kalinsky (46:36) Considerations in the Care of Patients with ER-Positive Metastatic Breast Cancer Preference of CDK4/6 inhibitor in the metastatic setting (56:42) Sequencing of trastuzumab deruxtecan in ER-positive, HER2-low metastatic breast cancer (59:00) Faculty presentation: Dr Jhaveri (1:06:39) Novel and Emerging Strategies for ER-Positive Metastatic Breast Cancer Selection of therapy for ER-positive metastatic breast cancer progressing on a CDK4/6 inhibitor; future role of capivasertib (1:19:31) Faculty presentation: Dr Rugo (1:30:39) Evolving Clinical Decision-Making for Localized Triple-Negative Breast Cancer (TNBC) Management of localized TNBC; selection of patients for adjuvant Olaparib (1:46:10) PARP inhibitor tolerability (1:51:55) Faculty presentation: Dr O'Shaughnessy (1:55:31) Recent Advances in the Treatment of Metastatic TNBC (mTNBC) Selection of therapy for triple-negative metastatic breast cancer; sequencing of trastuzumab deruxtecan in ER-negative, HER2-low disease (2:11:08) Faculty presentation: Prof Schmid (2:18:03) CME information and select publications

Featuring perspectives from Ms Brenda Martone and Dr Jonathan E Rosenberg, including the following topics: Introduction (0:00) Overview; Localized Urothelial Bladder Cancer (UBC) (3:56) First-Line Treatment of Metastatic Disease (34:16) Sequencing of Therapy for Metastatic UBC (59:44) NCPD information and select publications

Featuring perspectives from Dr Lyudmila A Bazhenova, Ms Kelly EH Goodwin, Dr Virginia Kaklamani, Ms Caroline Kuhlman, Ms Alexis N McKinney and Dr Zev Wainberg, including the following topics: Introduction (0:00) HER2 as a Therapeutic Target; Antibody-Drug Conjugates (6:15) HER2-Positive Breast Cancer (23:08) HER2-Positive Gastrointestinal Cancers (46:14) HER2-Positive Non-Small Cell Lung Cancer (1:08:14) Toxicities of Trastuzumab Deruxtecan (1:20:59) NCPD information and select publications

Featuring perspectives from Dr Edward B Garon, Dr John V Heymach, Dr Corey J Langer, Dr Ticiana Leal, Dr David R Spigel and Dr Helena Yu, including the following topics: Incorporation of Immunotherapeutic Strategies into the Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) Introduction (0:00) Strategies to cope with platinum shortages (3:11) Selection of appropriate candidates for neoadjuvant chemoimmunotherapy (5:51) Current clinical role of adjuvant anti-PD-1/PD-L1 antibodies (11:03) Patient selection for and practical implementation of consolidation durvalumab (15:40) Faculty presentation: Dr Heymach (18:05) Contemporary Treatment for Localized or Metastatic NSCLC with an EGFR Mutation Adjuvant osimertinib for EGFR mutation-positive localized NSCLC (29:45) Potential implications of FLAURA2 (35:43) Promising investigational strategies for progressive EGFR-mutant disease (38:15) Sequencing of therapies for metastatic NSCLC with EGFR exon 20 insertion mutations (42:01) Faculty presentation: Dr Yu (46:07) Research Advances Shaping the Current and Future Treatment of Metastatic NSCLC with ALK Rearrangements, ROS1 Rearrangements or RET Fusions Selection of first- and later-line treatment for ALK-rearranged NSCLC (54:36) Role of RET-targeted therapy in current clinical practice (56:53) Selection of therapy for ROS1-positive NSCLC, including for patients with CNS involvement (59:30) Faculty presentation: Dr Langer (1:01:25) Targeting MET, HER2 and KRAS Alterations in NSCLC Current clinical role of trastuzumab deruxtecan in NSCLC (1:16:14) Therapeutic sequencing for NSCLC with KRAS G12C mutations (1:20:41) Management of MET exon 14 mutation-positive NSCLC (1:24:33) Faculty presentation: Dr Spigel (1:29:36) Current Management of Metastatic NSCLC without a Targetable Tumor Mutation Anti-PD-1/PD-L1 antibodies for patients for whom biomarker testing is pending (1:38:48) Selection of first-line therapy for newly diagnosed metastatic NSCLC without a targetable tumor mutation (1:41:13) Role of first-line immunotherapy in PD-L1-negative metastatic NSCLC (1:44:17) Implications of antibiotic use and autoimmune toxicity for checkpoint inhibitor efficacy (1:48:15) Faculty presentation: Dr Garon (1:53:41) Future Directions in the Management of Metastatic NSCLC Future directions in NSCLC: Tumor treating fields and datopotamab deruxtecan (2:04:14) Faculty presentation: Dr Leal (2:13:18) CME information and select publications

Featuring perspectives from Dr Christopher R Flowers, Ms Amy Goodrich, Ms Robin Klebig and Dr Matthew Lunning, including the following topics: Introduction (0:00) POLARIX: Polatuzumab Vedotin/R-CHP for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (5:55) Polatuzumab Vedotin/Bendamustine/Rituximab and Selinexor for Relapsed Disease (24:28) CD19-Directed Antibody-Drug Conjugate Loncastuximab Tesirine (42:43) CD19-Directed Monoclonal Antibody Tafasitamab Combined with Lenalidomide (51:16) CD20 x CD3 Bispecific Antibodies (1:01:02) CAR (Chimeric Antigen Receptor) T-Cell Therapy (1:19:07) NCPD information and select publications

Featuring perspectives from Dr Brian Van Tine, including the following topics: Introduction (0:00) Case: A man in his mid 30s with metastatic recurrence of alveolar soft part sarcoma of the shoulder who received ipilimumab/nivolumab; imaging scan suspect for pseudoprogression — Nam Q Bui, MD (11:20) Case: A woman in her mid 30s with a 3-cm desmoid tumor who refuses treatment and is followed for 4 years, now with spontaneous tumor regression — Atif Hussein, MD, MMM (25:11) Case: A woman in her late teens with an unresectable, massive 14-cm desmoid tumor who receives sorafenib but has poor tolerance to treatment — Dr Hussein (32:35) Case: A woman in her early 40s with prior mastectomy for angiosarcoma of the right breast and recurrent disease who receives doxorubicin but develops a bleeding sigmoid mass and widespread metastases — Melanie B Thomas, MD (43:36) Case: A man in his mid 30s with a 5.5-cm leiomyosarcoma, 1 positive inguinal node and multiregimen-refractory disease — Dr Hussein (53:34) Case: A woman in her early 50s with past medical history of anemia, renal cell carcinoma and nephrectomy who is diagnosed with Grade I gastrointestinal stromal tumors, spindle cell type; c-KIT mutation — Dr Thomas(59:00) CME information and select publications

Featuring perspectives from Ms Ilene Galinsky, Dr Ruben A Mesa, Dr Daniel A Pollyea, Dr Richard M Stone and Dr Sara M Tinsley-Vance, including the following topics: Introduction (0:00) Overview of Myeloproliferative Neoplasms and Myelofibrosis (MF) — Impact of Ruxolitinib (5:28) New Agents in MF — Fedratinib, Momelotinib, Pacritinib (31:13) Myelodysplastic Syndromes — Management of Low- and High-Risk Disease (52:59) Overview of Acute Myeloid Leukemia (AML) (1:15:18) Targeted Therapy for AML (1:26:02) NCPD information and select publications